Overview

Atrasentan in Patients With IgA Nephropathy

Status:
Recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.

Phase:

Phase 3

Details

Lead Sponsor:

Chinook Therapeutics U.S., Inc.

Treatments:

Atrasentan